Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

• Published in: BMC cancer Vol. 18; no. 1; pp. 784 - 16
• Main Authors: Offman, Judith, Muldrew, Beth, O’Donovan, Maria, Debiram-Beecham, Irene, Pesola, Francesca, Kaimi, Irene, Smith, Samuel G., Wilson, Ashley, Khan, Zohrah, Lao-Sirieix, Pierre, Aigret, Benoit, Walter, Fiona M., Rubin, Greg, Morris, Steve, Jackson, Christopher, Sasieni, Peter, Fitzgerald, Rebecca C.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.08.2018; BioMed Central; BMC
• Subjects: Acid reflux; Acids; Analysis; Barrett esophagus; Barrett Esophagus - diagnosis; Barrett Esophagus - etiology; Barrett's esophagus; Biological markers; Biomarker; Biomarkers; Cancer; Chronic Disease; Clinical trials; Diagnosis; Disease Progression; Early detection; Early Detection of Cancer - methods; Endoscopy; Endoscopy, Digestive System - instrumentation; Endoscopy, Digestive System - methods; Equipment Design; Esophageal cancer; Esophageal Neoplasms - diagnosis; Esophagus; Female; Gastroenterology; Gastroesophageal reflux; Gastroesophageal Reflux - complications; Heartburn; Humans; Male; Medical equipment; Medical prognosis; Medical screening; Medical tests; Middle Aged; Oesophageal cancer; Patient satisfaction; Primary care; Primary Health Care; Study Protocol; Acid reflux; Oesophageal cancer; Biomarker; Cost effectiveness; Medical device; Endoscopy; Acceptability; Early detection; Heartburn; Quality of life

Early detection of oesophageal cancer improves outcomes; however, the optimal strategy for identifying patients at increased risk from the pre-cancerous lesion Barrett's oesophagus (BE) is not clear. The Cytosponge, a novel non-endoscopic sponge device, combined with the biomarker Trefoil Facto...